Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 2/20 | 0.56 |
| ▸ | CTSL | P07711 | 6/20 | 0.55 |
| ▸ | CTSB | P07858 | 6/20 | 0.55 |
| ▸ | CTSS | P25774 | 3/20 | 0.55 |
| ▸ | CTSK | P43235 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | CASP1 | P29466 | 1/20 | 0.53 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17039822 | 0.84 | TACR1 (0.55) | TACR1CTSLCTSBCTSSCTSK | |
| SCHEMBL14488100 | 0.84 | TACR1 (0.55) | TACR1CTSLCTSBCTSSCTSK | |
| SCHEMBL10977849 | 0.84 | ITGB3 (0.57) | TACR1CTSLCTSBCTSSCTSK | |
| SCHEMBL5689118 | 0.84 | TACR1 (0.55) | TACR1CTSLCTSBCTSSCTSK | |
| SCHEMBL19203669 | 0.84 | CTSL (0.52) | TACR1CTSLCTSBCTSSCTSK | |
| SCHEMBL11257246 | 0.83 | TACR1 (0.63) | TACR1CTSLCTSBCTSSCTSK | |
| SCHEMBL11257249 | 0.83 | TACR1 (0.63) | TACR1CTSLCTSBCTSSCTSK | |
| SCHEMBL30604928 | 0.81 | CTSB (0.60) | CTSLCTSBCTSSCTSKCASP1 | |
| SCHEMBL8750811 | 0.81 | TACR1 (0.60) | TACR1CTSLCTSBCTSSCTSK | |
| SCHEMBL8750802 | 0.81 | TACR1 (0.60) | TACR1CTSLCTSBCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210253634-A1 | PROCESS FOR THE LIQUID PHASE SYNTHESIS OF H-INP-(D)BAL-(D)TRP-PHE-APC-NH2, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | ALLERGAN GI CORP (US) | 2021-08-19 | — | — | US | disclosed |
| US-20200172572-A1 | PROCESS FOR THE LIQUID PHASE SYNTHESIS OF H-INP-(D)BAL-(D)TRP-PHE-APC-NH2, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | ALLERGAN GI CORP (US) | 2020-06-04 | — | — | US | disclosed |
| US-20170218015-A1 | PROCESS FOR THE LIQUID PHASE SYNTHESIS OF H-INP-(D)BAL-(D)TRP-PHE-APC-NH2, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | ALLERGAN GI CORP. | 2017-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253634-A1 | PROCESS FOR THE LIQUID PHASE SYNTHESIS OF H-INP-(D)BAL-(D)TRP-PHE-APC-NH2, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | VIP, IAPP, PROKR1 | TACR1 170/4885CTSL 1982/4885CTSB 4008/4885 |
| US-20200172572-A1 | PROCESS FOR THE LIQUID PHASE SYNTHESIS OF H-INP-(D)BAL-(D)TRP-PHE-APC-NH2, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | VIP, IAPP, PROKR1 | TACR1 170/4885CTSL 1982/4885CTSB 4008/4885 |
| US-20170218015-A1 | PROCESS FOR THE LIQUID PHASE SYNTHESIS OF H-INP-(D)BAL-(D)TRP-PHE-APC-NH2, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | VIP, IAPP, PROKR1 | TACR1 170/4885CTSL 1982/4885CTSB 4008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.